LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters
Viruses · 2023
DOI: 10.3390/v15071409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Warren R J de Moor und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town 7925, South Africa. Hauptthemen laut MEDLINE: COVID-19, Lumpy skin disease virus, Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCT Innovation Builder Fund, South African Research Chairs Initiative of the Department of Science and Technology and the National Research Foundation, EDCTP2 program.
Abstract (Originalsprache)
The SARS-CoV-2 pandemic demonstrated the need for potent and broad-spectrum vaccines. This study reports the development and testing of a lumpy skin disease virus (LSDV)-vectored vaccine against SARS-CoV-2, utilizing stabilized spike and conserved nucleocapsid proteins as antigens to develop robust immunogenicity. Construction of the vaccine (LSDV-SARS2-S,N) was confirmed by polymerase chain reaction (PCR) amplification and sequencing. In vitro characterization confirmed that cells infected with LSDV-SARS2-S,N expressed SARS-CoV-2 spike and nucleocapsid protein. In BALB/c mice, the vaccine elicited high magnitude IFN-γ ELISpot responses (spike: 2808 SFU/106 splenocytes) and neutralizing antibodies (ID50 = 6552). Testing in hamsters, which emulate human COVID-19 disease progression, showed the development of high titers of neutralizing antibodies against the Wuhan and Delta SARS-CoV-2 variants (Wuhan ID50 = 2905; Delta ID50 = 4648). Additionally, hamsters vaccinated with LSDV-SARS2-S,N displayed significantly less weight loss, lung damage, and reduced viral RNA copies following SARS-CoV-2 infection with the Delta variant as compared to controls, demonstrating protection against disease. These data demonstrate that LSDV-vectored vaccines display promise as an effective SARS-CoV-2 vaccine and as a potential vaccine platform for communicable diseases in humans and animals. Further efficacy testing and immune response analysis, particularly in non-human primates, are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town 7925, South Africa.
- Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
- International Centre for Genetic Engineering and Biotechnology, Observatory, Cape Town 7925, South Africa.
- Wellcome Trust Centre for Infectious Disease Research in Africa, University of Cape Town, Cape Town 7925, South Africa.
- Pathcare VetLab, Cape Town 7463, South Africa.
- Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University Tygerberg Campus, Cape Town 7505, South Africa.
ORCID-Profile: Warren R J de Moor, Anna-Lise Williamson, Georgia Schäfer, Nicola Douglass, Melissa J Blumenthal, Wolfgang Preiser, Rosamund Chapman
Förderung
- UCT Innovation Builder Fund
- South African Research Chairs Initiative of the Department of Science and Technology and the National Research Foundation
- EDCTP2 program
- Poliomyelitis Research Foundation
- NRF
- South African Medical Research Council
- ACSR Young Investigator Pilot Award
Zitieren
APA
de Moor, W. R. J., Williamson, A. L., Schäfer, G., Douglass, N., Gers, S., Sutherland, A. D., Blumenthal, M. J., Margolin, E., Shaw, M. L., Preiser, W., & Chapman, R. (2023). LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters. Viruses. https://doi.org/10.3390/v15071409
Vancouver
de Moor WRJ, Williamson AL, Schäfer G, Douglass N, Gers S, Sutherland AD, et al. LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters. Viruses. 2023. doi:10.3390/v15071409
BibTeX
@article{deMoor2023,
author = {de Moor, Warren R J and Williamson, Anna-Lise and Schäfer, Georgia and Douglass, Nicola and Gers, Sophette and Sutherland, Andrew D and Blumenthal, Melissa J and Margolin, Emmanuel and Shaw, Megan L and Preiser, Wolfgang and Chapman, Rosamund},
title = {LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15071409}
}
EUVIMED